Investor Relations

The Ambu share has a track record of high performance. And growth is a strong parameter for our success

Latest news


Oct. 2018

Ambu brings single-use technology to ENT

Innovation: The launch of two endoscopes for ear, nose and throat (ENT) procedures gives doctors and patients the choice of single-use to improve workflow and patient safety.

Danish medtech company, Ambu, has developed two single-use rhinolaryngoscopes to offer ear, nose and throat specialists an alternative to reusable scopes. Reusable scopes require complex reprocessing before they can be used on the next patient, whereas single-use scopes are guaranteed sterile for each patient.

The first single-use ENT scope is CE-marked and released for sale now, and the second will be brought to market before summer 2019.

A sterile scope
Guidelines for the disinfection of reusable ENT scopes are becoming increasingly strict. As facilities contend with these more rigorous cleaning requirements, there is a growing need for a better way to ensure safety without compromising efficiency.

We believe that each patient deserves a sterile scope – not just because snot and blood is unhygienic – but because a truly clean scope is the best way to avoid exposing patients to the risk of device-related cross-contamination,” says Lars Marcher, CEO of Ambu. “We have ten years of experience with the development of single-use scopes for use in the lungs, and we have used this expertise to develop two types of ENT scopes that increase patient safety and improve the workflow of ear, nose and throat specialists.

Better medical workflow
A single-use scope simplifies the workflow of the healthcare professional because it eliminates a number of costly and time-consuming tasks associated with reusable scopes, including cleaning and repairs. As it is single-use, there is no need to establish a new, more complicated workflow or make significant investments due to increased cleaning requirements.

The two types of single-use ENT scopes are:

  • Ambu® aScope™ 4 RhinoLaryngo Intervention – for speciality procedures
  • Ambu® aScope™ 4 RhinoLaryngo Slim – for routine inspections

Part of a broader range of single-use endoscopes
Ambu is the global market leader within single-use bronchoscopes (for procedurers in the upper airways and lungs). The key benefit of single-use is that patients are not exposed to cross-contamination from devices that have been used in other patients.

As well as in ENT, Ambu is now introducing single-use colonoscopes and will – within the next two years – also introduce single-use cystoscopes, gastroscopes and duodenoscopes (for use in the bladder, esophagus, stomach, and duodenum).

Europe and Australia now, USA in 2019
aScope 4 RhinoLaryngo has been developed in collaboration with ENT experts from across Europe. aScope 4 RhinoLaryngo Intervention is now released for sale in Europe, and Australia will follow in November 2018. Ambu expects to have market clearance for sales in the US before summer 2019. In addition, aScope 4 RhinoLaryngo Slim is expected to be released for sales in Europe, Australia and US before summer 2019.


What is a rhinolaryngoscope?
A rhinolaryngoscope is used by ENT specialists to visualize the airway anatomy from the nasal cavity down to the vocal folds. The scope is used to check a wide variety of conditions and perform specalized procedures such as biopsies, foreign body removal and suctioning procedures.


From the patient’s perspective
Imagine that you have an appointment with an ENT specialist tomorrow. You will be examined by having a flexible scope with a tiny camera placed through your nose to check your upper airway.

You will be given a choice of a scope that has been used on other patients that same day and a scope that is only used on you.

Which one would you choose?


Read more
Go to to read more about Ambu® aScope™ 4 RhinoLaryngo.

You can download this press release: Ambu brings single-use scopes to ENT (pdf).

The Ambu® aScope™ 4 RhinoLaryngo Intervention used for nasal procedure. The monitor – Ambu® aView™ – is not in direct contact with the patients and is reusable.


Oct. 2018

Ambu updates 2020 strategy and upgrades financial targets in connection with capital markets day 2018 (no. 1)

One year into the strategy period Ambu is ready to launch four new products and upgrade the long-term financial targets for 2020. 

On October 4th 2017, Ambu launched the strategy named Big Five 2020 including financial targets to be achieved in 2020. The strategy runs for three years and the first year of the strategy has just ended.

During this first year we have:

  • closed the acquisition of Invendo Medical GmbH which gives us a comprehensive technology platform on which to build a GI endoscope portfolio within this strategy period,
  • exceeded our initial financial targets for 2017/18 and positioned Ambu for higher future growth and earnings,
  • positioned Ambu as the front runner within single-use endoscopy in a market where several significant players have now announced their entrance.

The financial targets for Big Five 2020 are focused on growth and earnings expansion. To become successful, it will require a high consistent growth and a significant pipeline of new product launches to support this growth. At the capital markets day today, October 4th 2018, Ambu will announce significant progress on these topics.

Long term guidance towards 2020
In connection with the capital markets day 2018 Ambu will today announce the launches of four new products as well as demonstrate a prototype version of the single-use duodenoscope which is expected to be ready for commercial use before the completion of the Big Five 2020 time period.

The four new products that will be launched during 2018/19 are:

  • Q1 2018/19: Single-use colonoscope referred to as SC210,
  • Q1 2018/19: Single-use rhinolaryngoscope – aScope™ 4 RhinoLaryngo Intervention – to be used for ENT procedures (Ear, Nose and Throat),
  • Q1 2018/19: Single-use accessory to Ambu’s bronchoscope to be used for improving BAL procedures (bronchoalveolar lavage) in hospitals – aScope BronchoSampler™
  • Before summer 2019: Single-use rhinolaryngoscope – aScope™ 4 RhinoLaryngo Slim – to be used for ENT procedures  (Ear, Nose and Throat).

Based on the results achieved in the financial year 2017/18 and with growth contribution from the four product launches referred above, Ambu will raise its financial targets towards 2020 as follows:

  • Target revenue CAGR for the three-year plan to be increased from “13-15%” to “16-18%”,
  • Target EBIT margin in 2019/20 to be lifted from “24-25%” to “26-28%”,
  • Target FCF to be maintained at “~18% of revenue in 2019/20”.

The long term guidance now includes organic revenue contributed by the acquisition of Invendo Medical.

Guidance for the financial year 2018/19 that began on October 1, 2018
For the financial year 2018/19, we expect an organic growth rate in the level of 15-16%, an EBIT-margin in the interval 22-24% and a free cash flow generation in the interval DKK 400-475m equal to 14-15% of revenue. 

Guidance for the financial year 2017/18 that ended on September 30, 2018
The outlook for the financial year 2017/18 remains unchanged compared to the latest guidance provided on August 23, 2018. This is an organic growth of approx. 15%, an EBIT margin of approx. 21-22% and free cash flows of approx. DKK 300m.

You can download this company announcement (pdf).


Sep. 2018

Financial diary (no. 35)

Financial Diary 2018/19

30 October 2018
Deadline for the inclusion of specific items on the agenda of the annual general meeting 2017/18

13 November 2018
Annual Report 2017/18 (Earnings release)

12 December 2018
Ordinary Annual General Meeting

31 January 2019
Report for Q1 2018/19

1 May 2019
Report for Q2 2018/19

22 August 2019
Report for Q3 2018/19

30 September 2019
End of fiscal year 2018/19

Financial Diary 2019/20

4 November 2019
Deadline for the inclusion of specific items on the agenda of the annual general meeting 2018/19

12 November 2019
Annual Report 2018/19 (earnings release)

17 December 2019
Ordinary Annual General Meeting

You can download the financial diary (pdf).

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more


Get the latest investor presentations and webcasts
Read more


Learn more about Ambu's present strategy
Read more

Upcoming events


Oct. 2018

Silent period until release of annual report


Oct. 2018

Deadline for the inclusion of specific items on the agenda of the annual general meeting 2017/18


Nov. 2018

Annual Report 2017/18 (Earnings release)

A conference call is held at 11.00 (CET). The conference can be followed via and is held in English.

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up